Ester Planas-Rigol

Ester Planas-Rigol

Auto-generated profile, based on publicly available information

Ester Planas-Rigol

Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMónica Pascual-García
Mónica Pascual-García
EBEster Bonfill-Teixidor
Ester Bonfill-Teixidor
EPEster Planas-Rigol
Ester Planas-Rigol
CRCarlota Rubio-Perez
Carlota Rubio-Perez
RIRaffaella Iurlaro
Raffaella Iurlaro
JSJoan Seoane
Joan Seoane
Cancer response to immunotherapy depends on the infiltration of CD8+ T cells and the presence of tumor-associated macrophages within tumors. Still, little is known about the determinants of these factors. We show that LIF assumes a crucial role in the regulation of CD8+ T cell tumor infiltration, while promoting the presence of protumoral tumor-associated macrophages. We observe that the blockade of LIF in tumors expressing high levels of LIF decreases CD206, CD163 and CCL2 and induces CXCL9 expression in tumor-associated macrophages. The blockade of LIF releases the epigenetic silencing of CXCL9 triggering CD8+ T cell tumor infiltration. The combination of LIF neutralizing antibodies with the inhibition of the PD1 immune checkpoint promotes tumor regression, immunological memory and an increase in overall survival.

1 July 2014 in Medicine
Verified
Journal Article
Open access
MAMarco A. Alba
Marco A. Alba
AGAna García-Martínez
Ana García-Martínez
SPSergio Prieto-González
Sergio Prieto-González
ITItziar Tavera-Bahillo
Itziar Tavera-Bahillo
MCMarc Corbera-Bellalta
Marc Corbera-Bellalta
MCMaria Cinta Cid
Maria Cinta Cid
Giant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therapeutic impact, and clinical consequences of relapses have been scarcely addressed. We conducted the present study to investigate the prevalence, timing, and characteristics of relapses in patients with GCA and to analyze whether a relapsing course is associated with disease-related complications, increased glucocorticoid (GC) doses, and GC-related adverse effects. The study cohort included 106 patients, longitudinally followed by the authors for 7.8 ± 3.3 years. Relapses were defined as reappearance of disease-related symptoms requiring treatment adjustment. Relapses were classified into 4 categories: polymyalgia rheumatica (PMR), cranial symptoms (including ischemic complications), systemic disease, or symptomatic large vessel involvement. Cumulated GC dose during the first year of treatment, time required to achieve a maintenance prednisone dose <10 mg/d (T10), <5 mg/d (T5), or complete prednisone discontinuation (T0), and GC-related side effects were recorded. Sixty-eight patients (64%) experienced at least 1 relapse, and 38 (36%) experienced 2 or more. First relapse consisted of PMR in 51%, cranial symptoms in 31%, and systemic complaints in 18%. Relapses appeared predominantly, but not exclusively, within the first 2 years of treatment, and only 1 patient developed visual loss. T10, T5, and T0 were significantly longer in patients with relapses than in patients without relapse (median, 40 vs 27 wk, p < 0.0001; 163 vs 89.5 wk, p = 0.004; and 340 vs 190 wk, p = 0.001, respectively). Cumulated prednisone dose during the first year was significantly higher in relapsing patients (6.2 ± 1.7 g vs 5.4 ± 0.78 g, p = 0.015). Osteoporosis was more common in patients with relapses compared to those without (65% vs 32%, p = 0.001). In conclusion, the results of the present study provide evidence that a relapsing course is associated with higher and prolonged GC requirements and a higher frequency of osteoporosis in GCA.

1 August 2017 in Autoimmunity Reviews
Verified
Journal Article
Closed access
MSMaxime Samson
Maxime Samson
MCMarc Corbera-Bellalta
Marc Corbera-Bellalta
SASylvain Audia
Sylvain Audia
EPEster Planas-Rigol
Ester Planas-Rigol
LMLaurent Martin
Laurent Martin
BBBernard Bonnotte
Bernard Bonnotte

1 July 2014 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SPSergio Prieto-González
Sergio Prieto-González
MDMarina Depetris
Marina Depetris
AGAna García-Martínez
Ana García-Martínez
GEGeorgina Espígol-Frigolé
Georgina Espígol-Frigolé
ITItziar Tavera-Bahillo
Itziar Tavera-Bahillo
MCMaria C Cid
Maria C Cid
Background Positron emission tomography (PET) scan is emerging as a promising imaging technique to detect large-vessel inflammation in giant cell arteritis (GCA). However, the lack of a standardised definition of arteritis based on 18fluorodeoxyglucose (FDG) uptake is an important limitation to the use of PET scan for diagnostic purposes. Objective To prospectively assess the intensity and distribution of FDG uptake at different vascular territories in patients with newly diagnosed GCA compared with controls. Methods 32 consecutive, biopsy-proven, GCA patients treated with glucocorticoids for ≤3 days were included. The control group consisted of 20 individuals, who underwent PET/CT for cancer staging. Maximal standardised uptake value (SUVm) was calculated at four aortic segments, supraaortic branches and iliac-femoral territory. Sensitivity and specificity was calculated by receiver–operator characteristic curves (ROC) analysis. Results Mean SUVm was significantly higher in patients than in controls in all vessels explored and correlated with acute-phase reactants and serum IL-6. Mean of the SUVm at all the vascular territories had an area under the curve (AUC) of 0.830, and a cut-off of 1.89 yielded a sensitivity of 80% and a specificity of 79% for GCA diagnosis. There were no significant differences in AUC among the vascular beds examined. Conclusions FDG uptake by large vessels has a substantial sensitivity and specificity for GCA diagnosis.

1 June 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
MCMarc Corbera-Bellalta
Marc Corbera-Bellalta
EPEster Planas-Rigol
Ester Planas-Rigol
ELEster Lozano
Ester Lozano
NTNekane Terrades-García
Nekane Terrades-García
MAMarco A Alba
Marco A Alba
MCMaria C Cid
Maria C Cid
Background Interferon γ (IFNγ) is considered a seminal cytokine in the pathogenesis of giant cell arteritis (GCA), but its functional role has not been investigated. We explored changes in infiltrating cells and biomarkers elicited by blocking IFNγ with a neutralising monoclonal antibody, A6, in temporal arteries from patients with GCA. Methods Temporal arteries from 34 patients with GCA (positive histology) and 21 controls were cultured on 3D matrix (Matrigel) and exposed to A6 or recombinant IFNγ. Changes in gene/protein expression were measured by qRT-PCR/western blot or immunoassay. Changes in infiltrating cells were assessed by immunohistochemistry/immunofluorescence. Chemotaxis/adhesion assays were performed with temporal artery-derived vascular smooth muscle cells (VSMCs) and peripheral blood mononuclear cells (PBMCs). Results Blocking endogenous IFNγ with A6 abrogated STAT-1 phosphorylation in cultured GCA arteries. Furthermore, selective reduction in CXCL9, CXCL10 and CXCL11 chemokine expression was observed along with reduction in infiltrating CD68 macrophages. Adding IFNγ elicited consistent opposite effects. IFNγ induced CXCL9, CXCL10, CXCL11, CCL2 and intracellular adhesion molecule-1 expression by cultured VSMC, resulting in increased PBMC chemotaxis/adhesion. Spontaneous expression of chemokines was higher in VSMC isolated from GCA-involved arteries than in those obtained from controls. Incubation of IFNγ-treated control arteries with PBMC resulted in adhesion/infiltration by CD68 macrophages, which did not occur in untreated arteries. Conclusions Our ex vivo system suggests that IFNγ may play an important role in the recruitment of macrophages in GCA by inducing production of specific chemokines and adhesion molecules. Vascular wall components (ie, VSMC) are mediators of these functions and may facilitate progression of inflammatory infiltrates through the vessel wall.

27 July 2017 in Blood
Verified
Journal Article
Open access
PDF file
PBPatricia Balsas
Patricia Balsas
JPJara Palomero
Jara Palomero
ÁEÁlvaro Eguileor
Álvaro Eguileor
MRMarta Leonor Rodríguez
Marta Leonor Rodríguez
MVMaria Carmela Vegliante
Maria Carmela Vegliante
VAVirginia Amador
Virginia Amador
SOX11 overexpression in Mantle Cell Lymphoma (MCL) has been associated with more aggresive behavior and worse outcome. However, SOX11 oncogenic pathways driving MCL tumor progression are poorly known. Here, we demonstrate that SOX11 binds to regulatory regions of two important genes for microenvironment-signals in cancer, (C-X-C motif) chemokine receptor 4 (CXCR4) and PTK2 (encoding for focal adhesion kinase (FAK)). Moreover, SOX11-positive xenograft and human primary MCL tumors overexpress cell migration and stromal stimulation gene signatures compared to their SOX11-negative counterparts. We show that SOX11 directly up-regulates CXCR4 and FAK expression, activating PI3K/AKT and ERK1/2 FAK-downstream pathways in MCL. Concordantly, SOX11-positive MCL cells have higher cell migration, transmigration through endothelial cells, adhesion to stromal cells and cell proliferation; and display an increased resistance to conventional drug therapies, compared to SOX11-negative MCL cells. Specific FAK inhibition blocks downstream PI3K/AKT- and ERK1/2-mediated phosphorylation. Additionally, specific FAK- and PI3K-inhibitors reduce SOX11-enhanced MCL cell migration and stromal-interactions, and revert cell adhesion mediated-drug resistance (CAM-DR), to the same levels as SOX11-negative MCL cells. In intravenous MCL xenograft models, SOX11-positive MCL cells display higher cell migration, invasion and growth compared to SOX11-knockdown cells, and specific FAK- and CXCR4-inhibitors impair SOX11-enhanced MCL engraftment in bone marrow. Overall, our results suggest that SOX11 promotes MCL homing and invasion, and increases CAM-DR through the direct regulation of CXCR4 and FAK expression and FAK/PI3K/AKT pathway activation, contributing to a more aggressive phenotype. Inhibition of this pathway may represent an efficient strategy to overcome stromal-mediated chemo-refractoriness in aggressive MCL. Key points SOX11 regulates MCL homing and invasion via direct regulation of CXCR4 and FAK expression, and PI3K/AKT and ERK1/2 signaling activation. SOX11 expression increases cell adhesion mediated-drug resistance (CAM-DR) contributing to a more aggressive MCL phenotype.